Publications by authors named "Ancilla Fernandes"

Claim this Profile
C
CKD progression, kidney failure, and mortality among US patients with IgA nephropathy.
John J Sim, Qiaoling Chen, Nancy Cannizzaro, Ancilla W Fernandes, Cibele Pinto

Nephrol Dial Transplant· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Association Between Surrogate Endpoints and Clinical Outcomes in Immunoglobulin A Nephropathy: A Systematic Literature Review.
Maria Lorenzi, Sarah N Ali, Sarah Cadarette, Stephen Ebohon, Vakaramoko Diaby, Ancilla W Fernandes

Adv Ther· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Response Rates and Kidney Outcomes among Adults with Primary FSGS.
John J Sim, Mercedes A Munis, Benjamin Lewing, Qiaoling Chen, Matthew Hill, Ancilla W Fernandes

Clin J Am Soc Nephrol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in US Clinical Practice With Comparison to Historical Control Data.
Ronald D Perrone, Diana Garbinsky, Sasikiran Nunna, Hema K Gandhi, Ancilla W Fernandes

Kidney Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Burden of corticosteroid therapy in patients with immunoglobulin A nephropathy (IgAN): a systematic literature review.
Sarah N Ali, Nicole Fusco, Dilip Makhija, Vakaramoko Diaby, Tosin Oladapo, Ancilla W Fernandes

BMC Nephrol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of Adult Primary Immunoglobulin A Nephropathy among a Racially/Ethnically Diverse Population in the United States.
John J Sim, Qiaoling Chen, Nancy Cannizzaro, Simran K Bhandari, Ancilla W Fernandes

Am J Nephrol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five years of post-marketing liver safety data from the tolvaptan Risk Evaluation and Mitigation Strategy.
Emanuel Lohrmann, Thomas Jaeger, Kene Enekebe, Zhen Zhang, Timothy Wilt, Ancilla W Fernandes

Clin Kidney J· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The incidence and prevalence of immunoglobulin A nephropathy in the United States.
Marc DeCongelio, Sarah N Ali, Martina Furegato, Sandipan Bhattacharjee, Ancilla W Fernandes

Clin Nephrol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolvaptan and Autosomal Dominant Polycystic Kidney Disease Progression in Individuals Aged 18-35 Years: A Pooled Database Analysis.
Fouad T Chebib, Neera Dahl, Xiaolei Zhou, Diana Garbinsky, Jinyi Wang, Ancilla W Fernandes

Kidney Med· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence and Proportion of Primary Focal Segmental Glomerulosclerosis (FSGS) among a Racially and Ethnically Diverse Adult Patient Population between 2010 and 2021.
Mercedes A Munis, Qiaoling Chen, T Matthew Hill, Min Zhuo, Asher D Schachter, Ancilla W Fernandes

Clin J Am Soc Nephrol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world data in lupus nephritis: results from a European survey on renal function testing and burden of disease progression.
Francesco Pesce, Ancilla Fernandes, David Clamp, Beatriz Asin, Emily Goddard

Curr Med Res Opin· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Liver safety of tolvaptan in patients with autosomal dominant polycystic kidney disease: interim data from a post-authorization safety study.
Thomas Jaeger, Emanuel Lohrmann, Adachukwu Ezenekwe, Kene Enekebe, Retesh Kumar, Ancilla W Fernandes

Clin Kidney J· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kidney Stone Disease and Progression Risk in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis of OVERTURE.
Berenice Y Gitomer, Michel Chonchol, Xiaolei Zhou, Diana Garbinsky, Jinyi Wang, Ancilla W Fernandes

Kidney360· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolvaptan and Number Needed to Harm in Autosomal Dominant Polycystic Kidney Disease.
Keith A Betts, Sasikiran Nunna, Retesh Kumar, Xiaoyu Nie, Ancilla W Fernandes

Kidney Med· April 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies.
Fouad T Chebib, Xiaolei Zhou, Diana Garbinsky, Eric Davenport, Sasikiran Nunna, Ancilla Fernandes

Kidney Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of tolvaptan discontinuation in patients with autosomal dominant polycystic kidney disease: a post hoc pooled analysis.
Michael Lioudis, Xiaolei Zhou, Eric Davenport, Sasikiran Nunna, Holly B Krasa, Ancilla W Fernandes

BMC Nephrol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world disease burden and outcomes of brain metastases in mutation-positive non-small-cell lung cancer.
Eric Nadler, Janet L Espirito, Melissa Pavilack, Bismark Baidoo, Ancilla Fernandes

Future Oncol· August 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Anne C Chiang, Ancilla W Fernandes, Melissa Pavilack, Jennifer W Wu, François Laliberté

BMC Cancer· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Observational Study of Treatment Patterns in Patients with Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer After First-Line EGFR-Tyrosine Kinase Inhibitors.
Eric Nadler, Melissa Pavilack, Janet L Espirito, Jamyia Clark, Ancilla Fernandes

Adv Ther· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Patient preferences for attributes of tyrosine kinase inhibitor treatments for EGFR mutation-positive non-small-cell lung cancer.
John Fp Bridges, Marie de la Cruz, Melissa Pavilack, Emuella Flood, Ellen M Janssen, Ancilla W Fernandes

Future Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The rate of occurrence, healthcare resource use and costs of adverse events among metastatic non-small cell lung cancer patients treated with first- and second-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Janakiraman Subramanian, Ancilla W Fernandes, François Laliberté, Melissa Pavilack, Maral DerSarkissian

Lung Cancer· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns and overall survival among patients with unresectable, stage III non-small-cell lung cancer.
Priyanka Bobbili, Kellie Ryan, Mei S Duh, Akanksha Dua, Ancilla W Fernandes

Future Oncol· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world treatment patterns among patients with unresected stage III non-small-cell lung cancer.
Kellie J Ryan, Karen E Skinner, Ancilla W Fernandes, Rajeshwari S Punekar, Melissa Pavilack

Future Oncol· September 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Complications and Economic Burden Associated With Obtaining Tissue for Diagnosis and Molecular Analysis in Patients With Non-Small-Cell Lung Cancer in the United States.
Ronan J Kelly, Ralph Turner, Yen-Wen Chen, James R Rigas, Ancilla W Fernandes

J Oncol Pract· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world outcomes in patients with unresected stage III non-small cell lung cancer.
Kellie J Ryan, Karen E Skinner, Ancilla W Fernandes, Rajeshwari S Punekar, Melissa Pavilack

Med Oncol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis